文献速递消化、代谢与肾脏急症

奥索昔单抗预防膝关节置换术后静脉血栓栓塞的效果:FOXTROT随机临床试验

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论在膝关节置换术患者中,术后奥索昔单抗0.6、1.2、1.8 mg/kg在术后10-13天静脉血栓栓塞发生率上非劣于依诺肝素,术前1.8 mg/kg优效于依诺肝素。

FOXTROT是一项在13个国家54家医院进行的随机、开放标签、裁决者盲法、2期非劣效性试验,纳入813例接受单侧膝关节置换术的成人患者。患者随机接受术后单次静脉奥索昔单抗0.3、0.6、1.2或1.8 mg/kg,术前0.3或1.8 mg/kg,或皮下依诺肝素40 mg每日一次,或口服阿哌沙班2.5 mg每日两次,至少10天或直至静脉造影。主要终点为术后10-13天静脉血栓栓塞发生率,非劣效界值为5%。术后奥索昔单抗0.6、1.2、1.8 mg/kg均达到非劣效标准,术前1.8 mg/kg达到优效标准;大出血或临床相关非大出血发生率奥索昔单抗最高4.7%,依诺肝素5.9%,阿哌沙班2%。作者结论认为需要进一步研究确立奥索昔单抗相对于标准血栓预防的疗效和安全性。

要点

  • 术后奥索昔单抗0.6 mg/kg组静脉血栓栓塞发生率15.7%,1.2 mg/kg组16.5%,1.8 mg/kg组17.9%,均非劣于依诺肝素组26.3%(风险差分别为10.6%、9.9%、8.4%,单侧95%CI下限均大于-5%)。
  • 术前奥索昔单抗1.8 mg/kg组静脉血栓栓塞发生率11.3%,优效于依诺肝素组26.3%(风险差15.1%,双侧90%CI 4.9%至25.2%)。
  • 术后和术前奥索昔单抗0.3 mg/kg未达到非劣效标准(风险差分别为2.6%和-3.6%,单侧95%CI下限低于-5%)。
  • 大出血或临床相关非大出血发生率:奥索昔单抗各组最高4.7%,依诺肝素组5.9%,阿哌沙班组2%。
  • 作者结论认为需要进一步研究确立奥索昔单抗相对于标准血栓预防的疗效和安全性。

适用人群与场景

  • 接受单侧膝关节置换术的成人患者,随机时间为2017年10月至2018年8月,随访至2019年1月。

诊断标准与关键阈值

  • 主要终点为术后10-13天静脉血栓栓塞发生率,通过术后10-13天强制双侧静脉造影或确认的症状性深静脉血栓或肺栓塞评估。
  • 非劣效界值为5%,与依诺肝素比较。

处置流程与药物剂量

  • 术后单次静脉奥索昔单抗0.3 mg/kg(n=107)、0.6 mg/kg(n=65)、1.2 mg/kg(n=108)或1.8 mg/kg(n=106)。
  • 术前单次静脉奥索昔单抗0.3 mg/kg(n=109)或1.8 mg/kg(n=108)。
  • 皮下依诺肝素40 mg每日一次(n=105)或口服阿哌沙班2.5 mg每日两次(n=105),至少10天或直至静脉造影。

研究设计与关键结果

  • 随机、开放标签、裁决者盲法、2期非劣效性试验,在13个国家54家医院进行,813例随机,600例纳入符合方案人群用于主要分析。
  • 主要终点发生率:术后奥索昔单抗0.3 mg/kg组23.7%(18例),0.6 mg/kg组15.7%(8例),1.2 mg/kg组16.5%(13例),1.8 mg/kg组17.9%(14例);术前奥索昔单抗0.3 mg/kg组29.9%(23例),1.8 mg/kg组11.3%(9例);依诺肝素组26.3%(20例);阿哌沙班组14.5%(12例)。
  • 与依诺肝素比较的风险差(单侧95%CI):术后0.6 mg/kg组10.6%(95%CI -1.2%至∞),1.2 mg/kg组9.9%(95%CI -0.9%至∞),1.8 mg/kg组8.4%(95%CI -2.6%至∞),均达到非劣效标准。
  • 术前1.8 mg/kg组与依诺肝素比较风险差15.1%(双侧90%CI 4.9%至25.2%),达到优效标准。
  • 术后和术前0.3 mg/kg组与依诺肝素比较风险差分别为2.6%(单侧95%CI -8.9%至∞)和-3.6%(单侧95%CI -15.5%至∞),未达到非劣效标准。
  • 大出血或临床相关非大出血发生率:奥索昔单抗各组最高4.7%,依诺肝素组5.9%,阿哌沙班组2%。

证据类型、等级与局限

  • 证据类型:随机、开放标签、裁决者盲法、2期非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为:在膝关节置换术患者中,术后奥索昔单抗0.6、1.2、1.8 mg/kg达到非劣效于依诺肝素的标准,术前1.8 mg/kg达到优效于依诺肝素的标准;需要进一步研究确立奥索昔单抗相对于标准血栓预防的疗效和安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The efficacy of factor XIa inhibition for thromboprophylaxis is unknown. Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa.

OBJECTIVE: To compare different doses of osocimab with enoxaparin and apixaban for thromboprophylaxis in patients who have undergone knee arthroplasty.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, adjudicator-blinded, phase 2 noninferiority trial with observer blinding for osocimab doses, conducted at 54 hospitals in 13 countries. Adult patients undergoing unilateral knee arthroplasty were randomized from October 2017 through August 2018 and followed up until January 2019.

INTERVENTIONS: Single intravenous osocimab postoperative doses of 0.3 mg/kg (n = 107), 0.6 mg/kg (n = 65), 1.2 mg/kg (n = 108), or 1.8 mg/kg (n = 106); preoperative doses of 0.3 mg/kg (n = 109) or 1.8 mg/kg (n = 108); or 40 mg of subcutaneous enoxaparin once daily (n = 105) or 2.5 mg of oral apixaban twice daily (n = 105) for at least 10 days or until venography.

MAIN OUTCOMES AND MEASURES: The primary outcome was venous thromboembolism incidence between 10 and 13 days postoperatively (assessed by mandatory bilateral venography performed 10 to 13 days after surgery or confirmed symptomatic deep vein thrombosis or pulmonary embolism). A 5% noninferiority margin compared with enoxaparin was chosen. The primary safety outcome of major or clinically relevant nonmajor bleeding was assessed until 10 to 13 days postoperatively.

RESULTS: Of 813 randomized participants (mean [SD] age, 66.5 years [8.2 years]; body mass index, 32.7 [5.7]; and 74.2% women), 600 were included in the per-protocol population used for the primary analysis. The primary outcome occurred in 18 patients (23.7%) receiving 0.3 mg/kg, 8 (15.7%) receiving 0.6 mg/kg, 13 (16.5%) receiving 1.2 mg/kg, and 14 (17.9%) receiving 1.8 mg/kg of osocimab postoperatively; 23 (29.9%) receiving 0.3 mg/kg and 9 (11.3%) receiving 1.8 mg/kg of osocimab preoperatively; 20 (26.3%) receiving enoxaparin; and 12 (14.5%) receiving apixaban. Osocimab given postoperatively met criteria for noninferiority compared with enoxaparin with risk differences (1-sided 95% CIs) of 10.6% (95% CI, -1.2% to ∞) at the 0.6-mg/kg dose; 9.9% (95% CI, -0.9% to ∞) at the 1.2-mg/kg dose, and 8.4% (95% CI, -2.6 to ∞) at the 1.8-mg/kg dose. The preoperative dose of 1.8 mg/kg of osocimab met criteria for superiority compared with enoxaparin with a risk difference of 15.1%; 2-sided 90% CI, 4.9% to 25.2%). Postoperative and preoperative doses of 0.3 mg/kg of osocimab did not meet the prespecified criteria for noninferiority, with risk differences (1-sided 95% CIs) of 2.6% (95% CI, -8.9% to ∞) and -3.6% (95% CI, -15.5% to ∞), respectively. Major or clinically relevant nonmajor bleeding was observed in up to 4.7% of those receiving osocimab, 5.9% receiving enoxaparin, and 2% receiving apixaban.

CONCLUSIONS AND RELEVANCE: Among patients undergoing knee arthroplasty, postoperative osocimab 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg met criteria for noninferiority compared with enoxaparin, and the preoperative 1.8-mg/kg dose of osocimab met criteria for superiority compared with enoxaparin for the primary outcome of incidence of venous thromboembolism at 10 to 13 days postoperatively. Further studies are needed to establish efficacy and safety of osocimab relative to standard thromboprophylaxis.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03276143.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Weitz JI, Bauersachs R, Becker B, et al. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020. PMID: 31935028. doi:10.1001/jama.2019.20687

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。